Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice

Cancer Immunology, Immunotherapy

Volumn 59, Issue 9, 2010, Pages 1357-1365

  De Góes Rocha, Flávia Gomes ^a   Chaves, Karen Cristina Barbosa ^a   Chammas, Roger ^b   Peron, Jean Pierre Schatzmann ^b   Rizzo, Luiz Vicente ^c   Schor, Nestor ^a   Bellini, Maria Helena ^a,d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Albert Einstein Jewish Institute for Education and Research   (Brazil)

^d INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

Endostatin; Gene therapy; IL 2; Renal cancer

Indexed keywords

ALPHA2 INTEGRIN; ENDOSTATIN; RECOMBINANT INTERLEUKIN 2; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; HELPER CELL; IMMUNOMODULATION; KIDNEY CARCINOMA; LUNG METASTASIS; LUNG NODULE; LUNG WEIGHT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRAL GENE THERAPY;

ANIMALS; ANTIGENS, CD; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; ENDOSTATINS; GENE THERAPY; INTERLEUKIN-2; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; NIH 3T3 CELLS; SOLITARY PULMONARY NODULE; T-LYMPHOCYTES;

EID: 77955511923     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0865-6     Document Type: Article

References (47)

1. K Gupta JD Miller JZ Li MW Russell C Charbonneau 2008 Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review Cancer Treat Rev 34 193 205 10.1016/j.ctrv.2007.12.001 10.1016/j.ctrv.2007.12.001 18313224
2. WH Chow SS Devesa JL Warren JF Fraumeni Jr 1999 Rising incidence of renal cell cancer in the United States JAMA 281 1628 1631 10.1001/jama.281.17.1628 10235157 1:STN:280:DyaK1M3kvFagtA%3D%3D (Pubitemid 29211773)
3. JM Hollingsworth DC Miller S Daignault BK Hollenbeck 2007 Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis Cancer 109 1763 1768 10.1002/cncr.22600 10.1002/cncr.22600 17351954 (Pubitemid 46668538)
4. J Assouad B Petcova P Berna A Dujon C Foucault M Riquet 2007 Renal cell carcinoma metastases surgery: pathologic findings and prognostic factors Ann Thorac Surg 84 1114 1120 10.1016/j.athoracsur.2007.04.118 10.1016/j.athoracsur. 2007.04.118 17888956 (Pubitemid 47417869)
5. L Weiss JP Harlos J Torhost B Gunthard F Hartveit E Svendsen WL Huang E Grundmann M Eder M Zwicknagl HR Cochrane D Stock C Wright CHW Horne 1988 Metastatic patterns of renal carcinoma: an analysis of 687 necropsies J Cancer Res Clin Oncol 114 605 612 10.1007/BF00398185 3204107 1:STN:280: DyaL1M%2FnvFOnsA%3D%3D (Pubitemid 19011678)
6. H Saitoh 1981 Distant metastasis of renal adenocarcinoma Cancer 48 1487 1491 10.1002/1097-0142(19810915)48:6<1487::AID-CNCR2820480635>3.0.CO;2-9 7272969 1:STN:280:DyaL38%2FgtF2itw%3D%3D (Pubitemid 11042605)
7. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian SM Steinberg HX Chen SA Rosenberg 2003 A Randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 427 434 10.1056/NEJMoa021491 10.1056/NEJMoa021491 12890841 1:CAS:528:DC%2BD3sXms1Klu7w%3D (Pubitemid 36910021)
8. RJ Motzer MD Michaelson BG Redman GR Hudes G Wilding RA Figlin MS Ginsberg ST Kim CM Baum SE DePrimo JZ Li CL Bello CP Theuer DJ George BI Rini 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 24 10.1200/JCO.2005.02. 2574 16330672 1:CAS:528:DC%2BD28Xot1ChtA%3D%3D (Pubitemid 46630489)
9. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim I Chen PW Bycott CM Baum 2007 Figlin RA Sunitinib versus interferon alpha in metastatic renal-cell carcinoma N Engl J Med 356 115 124 10.1056/NEJMoa065044 17215529 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
10. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 10.1056/NEJMoa060655 17215530 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
11. M Parton M Gore T Eisen 2006 Role of cytokine therapy in 2006 and beyond for metastatic renal cell carcinoma J Clin Oncol 24 5584 5592 10.1200/JCO.2006.08.1638 10.1200/JCO.2006.08.1638 17158544 1:CAS:528: DC%2BD2sXmvVSqtg%3D%3D (Pubitemid 46631339)
12. SA Rosenberg MT Lotze LM Muul AE Chang FP Avis S Leitman WM Linehan CN Robertson RE Lee JT Rubin, et al. 1987 A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone N Engl J Med 316 889 897 3493432 1:STN:280:DyaL2s7ksVGitA%3D%3D
13. RI Fisher SA Rosenberg G Fyfe 2000 Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma Cancer J Sci Am 6 S55 S57 10685660
14. MB Atkins 2002 Interleukin-2: clinical applications Semin Oncol 29 12 17 10.1053/sonc.2002.33077 12068383 1:CAS:528:DC%2BD38Xltlaqtrg%3D
15. JC Yang RM Sherry SM Steinberg SL Topalian DJ Schwartzentruber P Hwu CA Seipp L Rogers-Freezer KE Morton DE White DJ Liewehr MJ Merino SA Rosenberg 2003 Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer J Clin Oncol 21 3127 3132 10.1200/JCO.2003.02.122 10.1200/JCO.2003.02.122 12915604 1:CAS:528:DC%2BD2cXpsVWqtb8%3D (Pubitemid 46606294)
16. RO Dillman C Church RK Oldham, et al. 1993 Inpatient continuous-infusion of interleukin-2 in 788 patients with cancer: the National Biotherapy Study Group experience Cancer 71 2358 2370 10.1002/1097-0142(19930401)71:7<2358:: AID-CNCR2820710730>3.0.CO;2-M 8453558 1:STN:280:DyaK3s3gtFCmsw%3D%3D
17. M Guida G Colucci 2007 Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet? Ann Oncol 18 vi149 vi152 10.1093/annonc/mdm245 10.1093/annonc/mdm245 17591810
18. R Kerbel J Folkman 2002 Clinical translation of angiogenesis inhibitors Nat Rev Cancer 2 727 739 10.1038/nrc905 10.1038/nrc905 12360276 1:CAS:528:DC%2BD38XnsVGrtb0%3D (Pubitemid 37328908)
19. J Folkman 2004 Endogenous angiogenesis inhibitors APMIS 112 496 507 10.1111/j.1600-0463.2004.apm11207-0809.x 10.1111/j.1600-0463.2004.apm11207-0809. x 15563312 1:CAS:528:DC%2BD2MXls1Ghtg%3D%3D (Pubitemid 39626056)
20. T Boehm J Folkman T Browder MS O'Relly 1997 Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature 390 404 407 10.1038/37126 10.1038/37126 9389480 1:CAS:528:DyaK2sXns12rsL8%3D (Pubitemid 28027321)
21. MS O'Reilly T Boehm Y Shing N Fukai G Vasios WS Lane E Flynn JR Birkhead BR Olsen J Folkman 1997 Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277 285 10.1016/S0092-8674(00)81848-6 10.1016/S0092- 8674(00)81848-6 9008168 (Pubitemid 28015876)
22. M Kirsch G Schackert PM Black 2000 Angiogenesis, metastasis, and endogenous inhibition J Neuro-oncology 50 173 180 10.1023/A:1006453428013 10.1023/A:1006453428013 1:STN:280:DC%2BD3Mzmsl2luw%3D%3D (Pubitemid 32166299)
23. EA Te Velde JM Vogten MFGB Gebbink JM Van Gorp EE Voest IHMB Rinkes 2002 Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model Br J Surg 89 1302 1309 10.1046/j.1365-2168.2002.02183.x 12296902 1:STN:280:DC%2BD38vos1Gjsw%3D%3D (Pubitemid 36002551)
24. EL Coutinho LNS Andrade R Chammas L Morganti N Schor MH Bellini 2007 Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma FASEB J 21 3153 3161 10.1096/fj.07-8412com 10.1096/fj.07-8412com 17513560 1:CAS:528:DC%2BD2sXhtFKntbvF
25. R Clarke 1997 Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models Breast Cancer Res Treat 46 255 278 10.1023/A:1005938428456 9478280 1:CAS:528:DyaK1cXhtFWmtLo%3D (Pubitemid 28029528)
26. TC Chou 2006 Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol Rev 58 621 681 10.1124/pr.58.3.10 16968952 1:CAS:528:DC%2BD28XhtVOhtLfL (Pubitemid 44403686)
27. DC Cho I Puzanov MM Regan T Schwarzberg V Seery MY Lee V Liu R Bhatt H Koon JW Mier JA Sosman MB Atkins DF McDermott 2009 Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma J Immunother 32 181 185 10.1097/CJI.0b013e3181952b1d 10.1097/CJI.0b013e3181952b1d 19238017 1:CAS:528:DC%2BD1MXit1Cju7Y%3D
28. HK Jensen F Donskov M Nordsmark N Marcussen H Von der Maase 2009 Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma Clin Cancer Res 15 1052 1058 10.1158/1078-0432.CCR-08-1296 10.1158/1078-0432.CCR-08-1296 19188179 1:CAS:528:DC%2BD1MXht1Onsrk%3D
29. JW Yockman WJ Kim CW Chang SW Kim 2007 Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma Gene Ther 14 1399 1405 10.1038/sj.gt.3302999 17653245 1:CAS:528:DC%2BD2sXhtVCkurfP (Pubitemid 47423739)
30. ® polymer-based delivery of interleukin-2 as a cancer treatment J Immunother. 29 524 535 10.1097/01.cji.0000211306.05869.25 16971808 1:CAS:528:DC%2BD28XpsVantLo%3D (Pubitemid 44395277)
31. WE Samlowski R Petersen S Cuzzocrea H Macarthur D Burton JR McGregor D Salvemini 2003 A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects Nat Med 9 750 755 10.1038/nm874 10.1038/nm874 12730689 1:CAS:528:DC%2BD3sXktFOnu78%3D (Pubitemid 36749225)
32. Amagai Y, Matsumoto M, Hojo K, Iguchi M, Wada T, Tanaka H, Ide N, Kato A, Shichijo M, Abe K (2010) Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models. Jpn J Clin Oncol. doi: 10.1093/jjco/hyp200
33. D Weinstat-Saslow PS Steeg 1994 Angiogenesis and colonization in the tumor metastatic process: basic and applied advances FASEB J 8 401 407 7513289 1:CAS:528:DyaK2cXivFGgsL0%3D
34. DM Elaraj DE White SM Steinberg L Haworth SA Rosenberg JC Yang 2004 A pilot study of antiangiogenic therapy with bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma J Immunother 27 259 264 10.1097/00002371-200407000-00001 15235386 1:CAS:528:DC%2BD2cXkslKgtb4%3D
35. A Dutour J Monteil F Paraf, et al. 2005 Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor Mol Ther 11 311 319 10.1016/j.ymthe.2004.10.008 10.1016/j.ymthe.2004.10.008 15668143 1:CAS:528:DC%2BD2MXms1Gksg%3D%3D
36. P Blezinger J Wang M Gondo A Quezada D Mehrens M French A Singhal S Sullivan A Rolland R Ralston W Min 1999 Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene Nat Biotechnol 17 343 348 10.1038/7895t 10.1038/7895 10207881 1:CAS:528: DyaK1MXitl2hsr0%3D (Pubitemid 29166035)
37. EA Te Velde A Reijerkerk D Brandsma JM Vogten Y Wu O Kranenburg EE Voest MFGB Gebbink IHMB Rinkes 2004 Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells Br J Cancer 92 729 735 10.1038/sj.bjc.6602385 1:CAS:528:DC%2BD2MXhsFWlt7c%3D
38. H Futami L Eader TT Back E Gruys HA Young RH Wiltrout BC Baguley 1992 Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives J Immunother 12 247 255 10.1097/00002371-199211000-00005 1477076 1:CAS:528:DyaK3sXhtl2gsbc%3D
39. K Sonouchi TA Hamilton CS Tannenbaum RR Tubbs R Bukowski JH Finke 1994 Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-and interleukin-2 Am J Pathol 144 747 755 8160774 1:CAS:528:DyaK2cXktVOjsL0%3D
40. A Ravaud N Trufflandier JM Ferrière M Debled J Palussière L Cany R Gaston S Mathoulin-Pélissier BN Bui 2003 Subcutaneous interleukin-2, interferon -2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial Br J Cancer 89 2213 2218 10.1038/sj.bjc.6601419 10.1038/sj.bjc.6601419 14676797 1:CAS:528:DC%2BD3sXpvVShur8%3D (Pubitemid 38168002)
41. N Verra R Jansen G Groenewegen H Mallo MJ Kersten A Bex FA Vyth-Dreese J Sein W van de Kasteele WJ Nooijen, et al. 2003 Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma Br J Cancer 88 1346 1351 10.1038/sj.bjc.6600915 10.1038/sj.bjc.6600915 12778059 1:CAS:528:DC%2BD3sXktFOgu7Y%3D (Pubitemid 36606413)
42. LD Butler CP Browne NK Layman P Riedl J Tang P Marder, et al. 1998 In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states Cancer Res 48 6081 6089
43. AH Idris K Iizuka HR Smith AA Scalzo WM Yokoyama 1998 Genetic control of natural killing and in vivo tumor elimination by the Chok locus J Exp Med 188 2243 2256 10.1084/jem.188.12.2243 9858511 1:CAS:528:DyaK1MXhtFaqtg%3D%3D (Pubitemid 29028497)
44. M Iguchi M Matsumoto K Hojo T Wada Y Matsuo A Arimura K Abe 2009 Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma Jpn J Clin Oncol 39 303 309 10.1093/jjco/hyp021 10.1093/jjco/hyp021 19336449
45. M Salmi R Grenman S Grenman E Nordman S Jalkanen 1995 Tumor endothelium selectively supports binding of IL-2-propagated tumor-infiltrating lymphocytes J Immunol 154 6002 6012 7751643 1:CAS:528:DyaK2MXlvVWguro%3D
46. H Irjala M Salmi K Alanen R Grenman S Jalkanen 2001 Vascular adhesion protein 1 mediates binding of immunotherapeutic effector cells to tumor endothelium J Immunol 166 6937 6943 11359855 1:CAS:528:DC%2BD3MXjvFaqs7s%3D
47. AEM Dirkx MGA Egbrink K Castermans DWJ Van der Schaft VLJL Thijssen RPM Dings L Kwee KH Mayo J Wagstaff JCA Bouma-ter Steege AW Griffioen 2006 Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and in tumors FASEB J 20 621 630 10.1096/fj.05-4493com 16581970 1:CAS:528:DC%2BD28Xjtlaqs70%3D (Pubitemid 44933306)